by Dave Mihalovic
November 15, 2013

from PreventDisease Website



Dave Mihalovic is a Naturopathic Doctor who specializes in vaccine research, cancer prevention and a natural approach to treatment.




The Office of the Gene Technology Regulator (OGTR) is on its way to approve a licence application from PaxVax Australia (PaxVax) for the intentional release of a GMO vaccine consisting of live bacteria into the environment in,

  • Queensland

  • South Australia

  • Western Australia

  • Victoria




According to the regulator, it qualifies as a limited and controlled release under section 50A of the Gene Technology Act 2000 (the Act).


PaxVax is seeking approval to conduct the clinical trial of a genetically modified live bacterial vaccine against cholera. Once underway the trial is expected to be completed within one year, with trial sites selected from local government areas (LGAs) in Queensland, South Australia, Victoria and Western Australia.


PaxVax has proposed a number of control measures they say will restrict the spread and persistence of the GM vaccine and its introduced genetic material, however there is always a possibility of these restrictions failing and infecting wildlife and ecosystems.

Aerial vaccines have used in the United States directed towards animals by the use of plastic packets dropped by planes or helicopters.


Sanofi (who is one of the largest vaccine manufacturers in the world) has subsidiary companies such as Merial Limited who manufacture Raboral, an oral live-virus poisonous to humans yet distributed wildlife in the masses.




In 2008 Michael Greenwood wrote an article for the Yale School of Public Health entitled, "
Aerial Spraying Effectively Reduces Incidence of West Nile Virus in Humans."


The article stated that the incidence of human West Nile virus (WNV) cases can be significantly reduced through large scale aerial spraying that targets adult mosquitoes, according to research by the Yale School of Public Health and the California Department of Public Health.

Under the mandate for aerial spraying for specific vectors that pose a threat to human health, aerial vaccines known as DNA Vaccine Enhancements and Recombinant Vaccine against WNV may be tested or used to "protect" the people from vector infection exposures.


DNA vaccine enhancements specifically use Epstein-Barr viral capside's with multi human complement class II activators to neutralize antibodies.


The recombinant vaccines against WNV use Rabbit Beta-globulin or the poly (A) signal of the SV40 virus. In early studies of DNA vaccines it was found that the negative result studies would go into the category of future developmental research projects in gene therapy.


During the studies of poly (A) signaling of the SV40 for WNV vaccines, it was observed that WNV will lie dormant in individuals who were exposed to chicken pox, thus upon exposure to WNV aerial vaccines the potential for the release of chicken pox virus would cause a greater risk to having adult onset Shingles.







In February 2009 to present date, aerial spraying for the WNV occurred in major cities within the State of California.


During spraying of Anaheim, CA a Caucasian female (age 50) was exposed to heavy spraying, while doing her daily exercise of walking several miles. Heavy helicopter activity occurred for several days in this area. After spraying, she experienced light headedness, nausea, muscle aches and increased low back pain.


She was evaluated for toxicological mechanisms that were associated with pesticide exposure due to aerial spraying utilizing advanced biological monitoring testing. The test results which included protein band testing utilizing Protein Coupled Response (PCR) methods were positive for KD-45.


KD-45 is the protein band for SV-40 Simian Green Monkey virus.


Additional tests were performed for Epstein-Barr virus capside and Cytomegalovirus which are used in bioengineering for gene delivery systems through viral protein envelope and adenoviral protein envelope technology.


The individual was positive for both; indicating a highly probable exposure to a DNA vaccination delivery system through nasal inhalation.






In the Quarterly FunVax Review in June, 2007, the report lists the objective of a project listed as ID: 149AZ2 as a preparation of a viral vector that will inhibit/decrease the expression of a specific disruption gene (VMAT2) within a human population.


It further indicates in the abstract that six method of virus dispersal were tested including high altitude release, water supply release, insect transmission, and various methods of diffusion.















Aerial Spraying Effectively Reduces Incidence of...

West Nile Virus in Humans

by Michael Greenwood

June 2008
from PublicHealth.Yale Website

recovered through WayBackMachine Website



The incidence of human West Nile virus cases can be significantly reduced through large-scale aerial spraying that targets adult mosquitoes, according to research by the Yale School of Public Health and the California Department of Public Health.

Ryan M. Carney, an M.P.H./M.B.A. student at Yale and the project’s lead researcher, examined infection rates in humans before and after planes applied an insecticide over two areas of Sacramento County, California.


The infection rate of people within the treated areas decreased significantly after spraying, compared to that within areas of the county that were not treated.

West Nile virus is transmitted to humans through the bite of an infected female mosquito and can lead to severe fever, encephalitis, paralysis and even death. The disease spread throughout all 58 counties of California in 2004, and Sacramento County was the area hardest hit in the United States in 2005.


The disease has appeared in all of the lower 48 states, with varying levels of intensity.

Over a period of several nights in the summer of 2005, two regions of the county measuring hundreds of square kilometers each were subjected to aerial spraying with the pyrethrin-based insecticide, EverGreen Crop Protection EC 60-6. It was the first time in state history that aerial insecticides had been applied over a large urban setting and that results were available from such well-defined application areas.

The two target areas had a combined population of 560,407 people. Prior to treatment, there were 48 documented cases of human infection from West Nile virus. The infection level fell to seven people following treatment with the insecticide and to zero post-incubation (14 days after treatment).


In contrast, the surrounding untreated areas (which had a combined population of 518,566 people) had 41 documented cases prior to treatment and 35 cases after spraying was completed in the treated areas.


The researchers concluded that the risk of infection in the untreated areas was approximately six times higher than it was in the treated areas after spraying.

“Aerial [spraying] is generally the most effective manner when the density of adult mosquito populations needs to be quickly reduced,” said Carney.


“This study provides the epidemiological framework for making more informed decisions and more rigorous evaluations of such treatments.”

The Sacramento-Yolo Mosquito and Vector Control District and California health officials decided to spray the two areas amidst a growing public health crisis in 2005 that had already resulted in several deaths statewide.


Still, the decision was controversial as some people in the targeted areas were concerned about possible side effects from such a large-scale application.


Some people in the untargeted areas, meanwhile, were upset that they were not being afforded the same protection as residents just a few miles away. The same insecticide is used on crops and has been approved by the U.S. Environmental Protection Agency.

Carney noted that if the decision is made to use aerial spraying, it is more effective to do it early in the West Nile virus transmission season, at the onset of amplification within mosquito and bird populations, rather than after human infection has set in.


The disease generally peaks in July and August.

Details of the research were published in the May issue of Emerging Infectious Diseases.